Common Stock Valuation Ratios (Price Multiples)
Quarterly Data
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Express Scripts Holding Co., historical price multiples (quarterly data)
Based on: 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31).
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Express Scripts Holding Co. P/E ratio decreased from Q1 2018 to Q2 2018 but then increased from Q2 2018 to Q3 2018 exceeding Q1 2018 level. |
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Express Scripts Holding Co. P/OP ratio increased from Q1 2018 to Q2 2018 and from Q2 2018 to Q3 2018. |
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Express Scripts Holding Co. P/S ratio increased from Q1 2018 to Q2 2018 and from Q2 2018 to Q3 2018. |
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | Express Scripts Holding Co. P/BV ratio decreased from Q1 2018 to Q2 2018 but then increased from Q2 2018 to Q3 2018 exceeding Q1 2018 level. |
Price to Earnings (P/E)
Express Scripts Holding Co., historical P/E calculation (quarterly data)
| Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 563,860,000 | 562,229,000 | 561,721,000 | 564,347,000 | 566,373,000 | 577,549,000 | 593,527,000 | 605,720,000 | 616,621,000 | 630,219,000 | 632,536,000 | 668,046,000 | 676,276,000 | 675,731,000 | 729,291,000 | 726,898,000 | 733,910,000 | 745,450,000 | 773,580,000 | 776,032,000 | 805,806,000 | 814,198,000 | 817,529,000 | |||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
| Net income attributable to Express Scripts (in thousands) | 1,071,600) | 877,300) | 623,200) | 2,327,600) | 841,700) | 801,800) | 546,300) | 1,434,700) | 722,900) | 720,700) | 526,100) | 773,500) | 661,700) | 600,100) | 441,100) | 581,800) | 582,300) | 515,200) | 328,300) | 501,900) | 426,700) | 543,000) | 373,000) | |||||||
| Earnings per share (EPS)2 | 8.69 | 8.31 | 8.18 | 8.00 | 6.40 | 6.07 | 5.77 | 5.62 | 4.45 | 4.26 | 4.05 | 3.71 | 3.38 | 3.26 | 2.91 | 2.76 | 2.63 | 2.38 | 2.33 | 2.38 | 0.00 | 0.00 | 0.00 | |||||||
| Share price1, 3 | 96.97 | 74.44 | 74.05 | 78.64 | 58.85 | 62.56 | 67.25 | 69.63 | 70.07 | 77.39 | 73.72 | 68.65 | 84.05 | 92.38 | 87.50 | 86.72 | 74.41 | 67.28 | 71.01 | 77.12 | 63.74 | 66.93 | 58.44 | |||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||
| P/E ratio4 | 11.16 | 8.96 | 9.05 | 9.82 | 9.20 | 10.31 | 11.66 | 12.39 | 15.75 | 18.19 | 18.21 | 18.52 | 24.88 | 28.31 | 30.09 | 31.40 | 28.33 | 28.30 | 30.52 | 32.44 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| P/E Ratio, Competitors5 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Cigna Group | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Humana Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Shockwave Medical Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2018 Calculation
EPS
= (Net income attributable to Express ScriptsQ3 2018
+ Net income attributable to Express ScriptsQ2 2018
+ Net income attributable to Express ScriptsQ1 2018
+ Net income attributable to Express ScriptsQ4 2017)
÷ No. shares of common stock outstanding
= (1,071,600,000 + 877,300,000 + 623,200,000 + 2,327,600,000)
÷ 563,860,000 = 8.69
3 Closing price as at the filing date of Express Scripts Holding Co. Quarterly or Annual Report.
4 Q3 2018 Calculation
P/E ratio = Share price ÷ EPS
= 96.97 ÷ 8.69 = 11.16
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Express Scripts Holding Co. P/E ratio decreased from Q1 2018 to Q2 2018 but then increased from Q2 2018 to Q3 2018 exceeding Q1 2018 level. |
Price to Operating Profit (P/OP)
Express Scripts Holding Co., historical P/OP calculation (quarterly data)
| Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 563,860,000 | 562,229,000 | 561,721,000 | 564,347,000 | 566,373,000 | 577,549,000 | 593,527,000 | 605,720,000 | 616,621,000 | 630,219,000 | 632,536,000 | 668,046,000 | 676,276,000 | 675,731,000 | 729,291,000 | 726,898,000 | 733,910,000 | 745,450,000 | 773,580,000 | 776,032,000 | 805,806,000 | 814,198,000 | 817,529,000 | |||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
| Operating income (in thousands) | 1,488,600) | 1,312,200) | 961,600) | 1,582,400) | 1,478,400) | 1,378,600) | 1,054,600) | 1,474,700) | 1,416,000) | 1,256,300) | 940,800) | 1,213,800) | 1,166,200) | 1,132,700) | 826,600) | 942,800) | 984,400) | 966,000) | 709,200) | 828,800) | 875,500) | 1,004,300) | 843,100) | |||||||
| Operating profit per share2 | 9.48 | 9.49 | 9.62 | 9.74 | 9.51 | 9.22 | 8.76 | 8.40 | 7.83 | 7.26 | 7.04 | 6.50 | 6.02 | 5.75 | 5.10 | 4.96 | 4.75 | 4.53 | 4.42 | 4.58 | 0.00 | 0.00 | 0.00 | |||||||
| Share price1, 3 | 96.97 | 74.44 | 74.05 | 78.64 | 58.85 | 62.56 | 67.25 | 69.63 | 70.07 | 77.39 | 73.72 | 68.65 | 84.05 | 92.38 | 87.50 | 86.72 | 74.41 | 67.28 | 71.01 | 77.12 | 63.74 | 66.93 | 58.44 | |||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||
| P/OP ratio4 | 10.23 | 7.85 | 7.70 | 8.08 | 6.19 | 6.79 | 7.67 | 8.29 | 8.95 | 10.66 | 10.47 | 10.57 | 13.97 | 16.06 | 17.15 | 17.50 | 15.65 | 14.84 | 16.07 | 16.85 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Cigna Group | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Humana Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Shockwave Medical Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2018 Calculation
Operating profit per share
= (Operating incomeQ3 2018
+ Operating incomeQ2 2018
+ Operating incomeQ1 2018
+ Operating incomeQ4 2017)
÷ No. shares of common stock outstanding
= (1,488,600,000 + 1,312,200,000 + 961,600,000 + 1,582,400,000)
÷ 563,860,000 = 9.48
3 Closing price as at the filing date of Express Scripts Holding Co. Quarterly or Annual Report.
4 Q3 2018 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 96.97 ÷ 9.48 = 10.23
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Express Scripts Holding Co. P/OP ratio increased from Q1 2018 to Q2 2018 and from Q2 2018 to Q3 2018. |
Price to Sales (P/S)
Express Scripts Holding Co., historical P/S calculation (quarterly data)
| Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 563,860,000 | 562,229,000 | 561,721,000 | 564,347,000 | 566,373,000 | 577,549,000 | 593,527,000 | 605,720,000 | 616,621,000 | 630,219,000 | 632,536,000 | 668,046,000 | 676,276,000 | 675,731,000 | 729,291,000 | 726,898,000 | 733,910,000 | 745,450,000 | 773,580,000 | 776,032,000 | 805,806,000 | 814,198,000 | 817,529,000 | |||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
| Revenues (in thousands) | 25,563,200) | 25,641,800) | 24,769,400) | 25,378,800) | 24,683,400) | 25,347,500) | 24,654,900) | 24,863,300) | 25,410,100) | 25,222,300) | 24,791,800) | 26,175,400) | 25,222,600) | 25,454,200) | 24,899,600) | 26,312,600) | 25,778,500) | 25,111,000) | 23,685,000) | 25,781,400) | 25,915,600) | 26,381,900) | 26,019,900) | |||||||
| Sales per share2 | 179.75 | 178.71 | 178.34 | 177.31 | 175.77 | 173.62 | 168.74 | 165.57 | 164.77 | 160.92 | 160.69 | 152.31 | 150.66 | 151.61 | 140.00 | 138.79 | 136.74 | 134.81 | 131.55 | 134.14 | 0.00 | 0.00 | 0.00 | |||||||
| Share price1, 3 | 96.97 | 74.44 | 74.05 | 78.64 | 58.85 | 62.56 | 67.25 | 69.63 | 70.07 | 77.39 | 73.72 | 68.65 | 84.05 | 92.38 | 87.50 | 86.72 | 74.41 | 67.28 | 71.01 | 77.12 | 63.74 | 66.93 | 58.44 | |||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||
| P/S ratio4 | 0.54 | 0.42 | 0.42 | 0.44 | 0.33 | 0.36 | 0.40 | 0.42 | 0.43 | 0.48 | 0.46 | 0.45 | 0.56 | 0.61 | 0.62 | 0.62 | 0.54 | 0.50 | 0.54 | 0.57 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| P/S Ratio, Competitors5 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Cigna Group | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Humana Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Shockwave Medical Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2018 Calculation
Sales per share
= (RevenuesQ3 2018
+ RevenuesQ2 2018
+ RevenuesQ1 2018
+ RevenuesQ4 2017)
÷ No. shares of common stock outstanding
= (25,563,200,000 + 25,641,800,000 + 24,769,400,000 + 25,378,800,000)
÷ 563,860,000 = 179.75
3 Closing price as at the filing date of Express Scripts Holding Co. Quarterly or Annual Report.
4 Q3 2018 Calculation
P/S ratio = Share price ÷ Sales per share
= 96.97 ÷ 179.75 = 0.54
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Express Scripts Holding Co. P/S ratio increased from Q1 2018 to Q2 2018 and from Q2 2018 to Q3 2018. |
Price to Book Value (P/BV)
Express Scripts Holding Co., historical P/BV calculation (quarterly data)
| Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 563,860,000 | 562,229,000 | 561,721,000 | 564,347,000 | 566,373,000 | 577,549,000 | 593,527,000 | 605,720,000 | 616,621,000 | 630,219,000 | 632,536,000 | 668,046,000 | 676,276,000 | 675,731,000 | 729,291,000 | 726,898,000 | 733,910,000 | 745,450,000 | 773,580,000 | 776,032,000 | 805,806,000 | 814,198,000 | 817,529,000 | |||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
| Total Express Scripts stockholders’ equity (in thousands) | 20,565,900) | 19,370,000) | 18,442,500) | 18,119,600) | 15,916,500) | 15,744,600) | 15,922,600) | 16,236,000) | 15,600,300) | 15,403,100) | 14,841,100) | 17,372,800) | 16,538,300) | 15,822,200) | 20,604,800) | 20,054,200) | 20,157,700) | 20,451,900) | 21,874,300) | 21,837,400) | 23,702,300) | 23,866,500) | 23,617,800) | |||||||
| Book value per share (BVPS)2 | 36.47 | 34.45 | 32.83 | 32.11 | 28.10 | 27.26 | 26.83 | 26.80 | 25.30 | 24.44 | 23.46 | 26.01 | 24.45 | 23.41 | 28.25 | 27.59 | 27.47 | 27.44 | 28.28 | 28.14 | 29.41 | 29.31 | 28.89 | |||||||
| Share price1, 3 | 96.97 | 74.44 | 74.05 | 78.64 | 58.85 | 62.56 | 67.25 | 69.63 | 70.07 | 77.39 | 73.72 | 68.65 | 84.05 | 92.38 | 87.50 | 86.72 | 74.41 | 67.28 | 71.01 | 77.12 | 63.74 | 66.93 | 58.44 | |||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||
| P/BV ratio4 | 2.66 | 2.16 | 2.26 | 2.45 | 2.09 | 2.29 | 2.51 | 2.60 | 2.77 | 3.17 | 3.14 | 2.64 | 3.44 | 3.95 | 3.10 | 3.14 | 2.71 | 2.45 | 2.51 | 2.74 | 2.17 | 2.28 | 2.02 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Cigna Group | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Humana Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 2.11 | 2.10 | 2.14 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Shockwave Medical Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2018 Calculation
BVPS = Total Express Scripts stockholders’ equity ÷ No. shares of common stock outstanding
= 20,565,900,000 ÷ 563,860,000 = 36.47
3 Closing price as at the filing date of Express Scripts Holding Co. Quarterly or Annual Report.
4 Q3 2018 Calculation
P/BV ratio = Share price ÷ BVPS
= 96.97 ÷ 36.47 = 2.66
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | Express Scripts Holding Co. P/BV ratio decreased from Q1 2018 to Q2 2018 but then increased from Q2 2018 to Q3 2018 exceeding Q1 2018 level. |